My Cart

Human CD16a (158V) (Luc) Jurkat Reporter Cell (CD3 Negative)

Cat. No. / Size
Price
Qty
CJUR-STF299-2Vials (1Vial X 2)
$17985.00
ETA of in-stock products:2 business days
Sub-Total$ 0

Product Details

    1. Genetically modified cell lines best reflect MOA (Mechanism of Action)
    2. Higher activity and larger assay window for robust and reproducible cell-based bioassay
    3. Comprehensive application data to support assay development and validation
    4. Full tracible record, stringent quality control and validated cell passage stability
    5. Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
    6. Global commercial license assistance whenever regulatory filing is required
  • Description

    The Human CD16a (158V) (Luc) Jurkat Reporter Cell (CD3 Negative) was engineered to not only express the NFAT signaling response element and the receptor full length human CD16a (Uniprot: P08637) mutated to a Valine (V) at amino acid 158 exhibiting a higher affinity for IgG1 and IgG3 isotypes compared to CD16a-158F, but also targeted knockout of the endogenous TCR chains resulting in loss of functional TCR/CD3 complex on the cell surface. When co-cultured with a target cell and the corresponding anti-TAA × CD3 bispecific antibody (BsAb), the anti-TAA × CD3 BsAb simultaneously binds both the target-associated antigen (TAA) on the target cell and the CD16a (158V) receptor on the Human CD16a (158V) (Luc) Jurkat Reporter Cell (CD3 Negative), resulting in receptor clustering, intracellular signaling and NFAT-mediated luminescence.

  • Application

    • Determination of ADCC activity induced by anti-TAA × CD3 BsAbs

    CD16A Assay Principles

  • Growth Properties

    Suspension

  • Selection Marker

    Puromycin (5 μg/mL) + Hygromycin (20 μg/mL) + Zeocin (20 μg/mL)

  • Complete Growth Medium

    RPMI-1640 + 10% FBS

  • Freeze Medium

    Serum-free cell cryopreservation medium

  • Quantity

    1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium

  • Storage

    Frozen in liquid nitrogen.

  • Mycoplasma Testing

    Negative

  • Sterility Testing

    Negative

  • Instructions for Use

    See data sheet for detailed culturing and assay protocol.

  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Customers Also Viewed

Performance Data

  • Receptor Assay

     CD16A FACS

    Expression analysis of human CD16a (158V) on Human CD16a (158V) (Luc) Jurkat Reporter Cell (CD3 Negative) by FACS.
    Cell surface staining was performed on Human CD16a (158V) (Luc) Jurkat Reporter Cell (CD3 Negative) or negative control cell using PE-labeled anti-human CD16a antibody.

    Protocol
  •  CD16A FACS

    Expression analysis of human TCR and human CD3 on Human CD16a (158V) (Luc) Jurkat Reporter Cell (CD3 Negative) by FACS.
    Cell surface staining was performed on Human CD16a (158V) (Luc) Jurkat Reporter Cell (CD3 Negative) using PE-labeled anti-human TCR antibody and APC-labeled anti-human CD3 antibody. The parental reporter cell (CD3 Positive) was used as the control. This result confirmed the loss of TCR/CD3 complex on the cell surface of Human CD16a (158V) (Luc) Jurkat Reporter Cell (CD3 Negative).

    Protocol
  • Signaling Bioassay

     CD16A SIGNALING

    ADCC response to anti-human CD20 antibody (RLU).
    Anti-human CD20 antibody-induced ADCC activity was evaluated using Human CD16a (158V) (Luc) Jurkat Reporter Cell (CD3 Negative) in the presence of Raji cells that express CD20 endogenously.The parental reporter cell lacking human CD16a (158V) expression was used as the control. The EC50 of anti-human CD20 antibody on the Human CD16a (158V) (Luc) Jurkat Reporter Cell (CD3 Negative) was approximately 0.0038 μg/mL.

    Protocol
  •  CD16A SIGNALING

    ADCC response to anti-human CD20 antibody (FOLD).
    Anti-human CD20 antibody-induced ADCC activity was evaluated using Human CD16a (158V) (Luc) Jurkat Reporter Cell (CD3 Negative) in the presence of Raji cells that express CD20 endogenously. The parental reporter cell lacking human CD16a (158V) expression was used as the control. The max induction fold on Human CD16a (158V) (Luc) Jurkat Reporter Cell (CD3 Negative) was approximately 718.04.

    Protocol
  •  CD16A SIGNALING

    Response to anti-human CD3 antibody (RLU).
    Human CD16a (158V) (Luc) Jurkat Reporter Cell (CD3 Negative) was incubated with serial dilutions of anti-human CD3 antibody (Cat. No. CDE-M120a). The parental reporter cell (CD3 Positive) was used as the control. Compared to the parental reporter cell (CD3 Positive), the Human CD16a (158V) (Luc) Jurkat Reporter Cell (CD3 Negative) exhibited no activation response to anti-human CD3 antibody stimulation.

    Protocol
  •  CD16A SIGNALING

    Response to anti-human CD3 antibody (FOLD).
    Human CD16a (158V) (Luc) Jurkat Reporter Cell (CD3 Negative) was incubated with serial dilutions of anti-human CD3 antibody (Cat. No. CDE-M120a). The parental reporter cell (CD3 positive) was used as the control. Compared to the parental reporter cell (CD3 Positive), the Human CD16a (158V) (Luc) Jurkat Reporter Cell (CD3 Negative) exhibited no activation response to anti-human CD3 antibody stimulation.

    Protocol
*Please contact us if you are interested in related cell pool service.

Customer Reviews
Writing Reviews

Important Statement

  • Limited Use&License Disclosure

    BY USE OF THIS PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE FOLLOWING TERMS OF LIMITED USE OF THIS CELL LINE PRODUCT.

    1. If the researcher is not willing to accept the terms of limited use of this cell line product, and the product is unused, ACRO will accept return of the unused product.
    2. Researchers may use this product for research use only, no commercial use is allowed. "Commercial use" means any and all uses of this product and derivatives by a party for profit or other consideration and may include but is not limited to use in: (1) product manufacture; and (2) to provide a service, information or data; and/or resale of the product or its derivatives, whether or not such product or derivatives are resold for use in research.
    3. This cell line is neither intended for any animal or human therapeutic purposes nor for any direct human in vivo use. You have no right to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
    4. ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
    5. ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
    6. Modifications of the cell line, transfer to a third party, or commercial use of the cell line may require a separate license and additional fees. Please contact order@acrobiosystems.com for further details.

Recent Advances

 
Contact Us
Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Customers Also Viewed
  • Performance Data
  • Customer Reviews
  • Important Statement
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland